Agemica

Our mission is to extend the healthy human lifespan to 150 years.

Aging takes away the people we love, the knowledge we build, and the futures we have yet to live. We believe it is a problem to solve.

Agemica brings artificial intelligence and experimental biology together to fight aging, cancer, and disease. We design therapeutic combinations, test them in human biological models, and advance the most promising candidates.

More time to discover. To build. To love. To see what comes next.

The people behind the mission

Prof. Ronjon Nag, Founder.
Stanford Adjunct Professor of Genetics. Cambridge PhD, MIT MS. His companies have been acquired by Apple, BlackBerry, and Motorola.

Dr. Yasaman Kalantar-Motamedi, Co-founder.
Cambridge PhD, UCL MSc in Machine Learning. Twelve years in AI drug discovery and vaccine design.

Prof. Michael Snyder, Scientific Advisor.
Chair of Stanford Genetics, 2009–2024. Director, Center for Genomics and Personalized Medicine. Co-founder of Personalis.

Dr. Jayakumar Rajadas, Scientific Advisor.
Founding Director of Stanford’s ADDReB laboratory. Thirty years in drug development. 260+ publications. 82+ patents.

Anastasiya Giarletta, Advisor.
Principal, R42 Group. AI, longevity, and the next generation of founders.

Proof of Work

Innovation Excellence Award, 2026.
Agemica won at the Life Sciences Innovation Forum, Riyadh Global Medical Biotechnology Summit. Announcement.

Thirty cancer types. Six lead combinations.
Agemica reports up to 100% cancer-cell death in selected human cancer models at seven days, and no observed cell death in tested healthy fibroblast controls. Cancer research. Healthy-cell controls.

Company-reported laboratory findings, ex vivo. Clinical efficacy and safety in humans remain to be established.

Published work in computational drug discovery.
Research by co-founder Yasaman Kalantar-Motamedi and collaborators, published in Scientific Reports, 2021. Read the paper.